Search

everythinglearnresearchcommunity

for

Search:↓

Mice with human fetal thymic tissue and stem cells developed symptoms similar to chronic graft-versus-host disease.

Alopecia areata involves immune system changes, especially in severe cases, with potential new treatment targets identified.

CD8+ T cells attack hair follicle stem cells, causing scarring and hair loss.

Skin cells control immune cell placement, helping the skin respond better to challenges.

Folliculotropic mycosis fungoides has unique molecular features and cell interactions that could guide targeted therapy.

Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.

M-CSF-stimulated myeloid cells can turn into skin cells and help heal wounds and regrow hair.

Certain immune cells, when activated by specific signals, can encourage hair growth.

A specific group of skin stem cells was found to help maintain hair follicle cells.

Bone marrow-derived cells contribute to skin tumors, suggesting new treatment targets for non-melanoma skin cancers.

Diphencyprone treatment increases CD8 lymphocytes in the scalp, which is associated with hair regrowth in alopecia areata patients.

Expanded CD8+ T cells are linked to Alopecia Areata and may cause relapse after treatment.

CD44 variant changes start alopecia areata, but don't maintain it.

Lacking cyclin D3 reduces skin cancer growth without affecting normal skin cell growth.

Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.

IL-1 and IL-7 help activate cells that boost hair follicle stem cell growth, aiding wound healing.

Psoriasis involves an imbalance between certain immune cells, and targeting these could help restore skin health.

The protein CCN2 controls hair growth by affecting hair follicle formation and stem cell activity in mice.

Different γδ T cell types have unique roles in causing alopecia areata.

The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.

T cells with memory features grow in number and gather around hair follicles when there are not enough immune cells.

CD8+ T cells are involved in alopecia areata and may cause disease relapse.

Certain genetic variations in IL-16 may increase the risk of alopecia areata.

Monoclonal antibody B72.3 selectively reacts with certain dog tissues, mainly in the gastrointestinal and respiratory tracts.

Alopecia areata patients have more activated T cells in their blood, which may help in developing treatments.

CD8+ virtual memory T cells may cause hair loss in alopecia areata.

Patients with Alopecia areata have fewer specific immune cells that normally regulate the immune system, which may contribute to the condition.

Enhancing Tregs can protect against alopecia areata.

Different types of resting melanocyte stem cells have unique characteristics and vary in their potential to become other cells.